Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtho.2019.05.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis on the pathogenesis and treatment progress of NRG1 fusion-positive non-small cell lung cancer.
Front Oncol
June 2024
Oncology Department of Integrated Traditional Chinese and Western Medicine, Shenyang Chest Hospital & Tenth People's Hospital, Shenyang, Liaoning, China.
Lung cancer persistently leads as the primary cause of morbidity and mortality among malignancies. A notable increase in the prevalence of lung adenocarcinoma has become evident in recent years. Although targeted therapies have shown in treating certain subsets of non-small cell lung cancers (NSCLC), a significant proportion of patients still face suboptimal therapeutic outcomes.
View Article and Find Full Text PDFThe phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring gene fusions.
Future Oncol
June 2024
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Neuregulin 1 () fusions are oncogenic drivers that have been detected in non-small-cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. fusions are rare, occurring in less than 1% of solid tumors. Patients with fusion positive (NRG1+) cancer have limited therapeutic options.
View Article and Find Full Text PDFReal-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Lung Cancer
February 2024
Durham Veterans Affairs Hospital, Durham, NC 27705, USA.
Objectives: Neuregulin-1 (NRG1) fusions may drive oncogenesis via constitutive activation of ErbB signaling. Hence, NRG1 fusion-driven tumors may be susceptible to ErbB-targeted therapy. Afatinib (irreversible pan-ErbB inhibitor) has demonstrated activity in individual patients with NRG1 fusion-positive solid tumors.
View Article and Find Full Text PDFHER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
J Thorac Oncol
January 2024
Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:
Article Synopsis
- NRG1 gene fusions are found in non-small cell lung cancer (NSCLC) and other tumors, but current targeting strategies for HER2 and HER3 have shown limited effectiveness.
- This study explores the role of HER4 and EGFR-HER3 signaling in NRG1 fusion-positive cancers using specialized cell models and in vivo cancer models.
- Results suggest that targeting both HER4 and EGFR, along with other HER family members, provides a more effective treatment approach compared to focusing solely on HER3 or HER2-HER3 in these cancers.
Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
World J Surg Oncol
August 2023
Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, No. 1 DaHua Road, Beijing, 100730, China.
Background: NRG1 fusions are rare oncogenic drivers in solid tumors, and the incidence of NRG1 fusions in non-small cell lung cancer (NSCLC) was 0.26%. It is essential to explore potential therapeutic strategies and efficacy predictors for NRG1 fusion-positive cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!